Old CIC Events
![KRAS driven lung adenocarcinoma depends on ERBB signaling](/media/1229/ef9646db7fec0d8650ec3240ee8f7cc5.jpg?width=350&height=200&mode=crop)
KRAS driven lung adenocarcinoma depends on ERBB signaling
Emilio Casanova-Hevia — Ludwig Boltzmann Institute Cancer Research [Vienna, Austria]
![Cell-of-origin of prostate cancer and clinical heterogeneity](/media/1230/482c5ebf3f5c5845fd7770967bc921f4.jpg?width=350&height=200&mode=crop)
Cell-of-origin of prostate cancer and clinical heterogeneity
Esther Baena Chaparro — Cancer Research UK Manchester Institute [Manchester, UK]
![CLINICAL IMPACT OF DNA REPAIR DEFECTS IN PROSTATE CANCER](/media/1231/b231895836c1c4e0ccd4f55e4eafebc4.jpg?width=350&height=200&mode=crop)
CLINICAL IMPACT OF DNA REPAIR DEFECTS IN PROSTATE CANCER
Elena Castro Marcos — Spanish National Cancer Research Centre (CNIO)
![Host-Microbiota Interactions in Health and Disease](/media/1228/5ea3ca685f651eda874b7c4f33327467.jpg?width=350&height=200&mode=crop)
Host-Microbiota Interactions in Health and Disease
Gabriel Núñez — University of Michigan [Michigan, USA]
![Novel targeted therapies in lymphoid neoplasia: from apoptosis activation to microenvironment harnessing](/media/1233/24e78b0282936361f843795eb2015b00.jpg?width=350&height=200&mode=crop)
Novel targeted therapies in lymphoid neoplasia: from apoptosis activation to microenvironment harnessing
Patricia Pérez Galán — IDIBAPS- Hospital Clinic, Barcelona
![MHC CLASS I LOSS AND CANCER IMMUNE ESCAPE](/media/1234/3b198d814965475f63595b7f5c6b295c.jpg?width=350&height=200&mode=crop)
MHC CLASS I LOSS AND CANCER IMMUNE ESCAPE
Federico Garrido — Universidad de Granada [Granada, Spain]
![CCR EN EL ADULTO JOVEN, UNA ENTIDAD DIFERENTE](/media/1235/f8d1789e1e4c7f0b376669d24b5777d4-1.jpg?width=350&height=200&mode=crop)
CCR EN EL ADULTO JOVEN, UNA ENTIDAD DIFERENTE
Jessica Pérez García — Centro de Investigación del Cáncer (CIC-IBMCC), Salamanca
![Inmunoterapia de síndromes linfoproliferativos y enfermedad de injerto contra huésped con anticuerpos contra el receptor de quimiocinas CCR7.](/media/1236/1776e3eb15d6dfcabecc52b62e4ee16d.jpg?width=350&height=200&mode=crop)
Inmunoterapia de síndromes linfoproliferativos y enfermedad de injerto contra huésped con anticuerpos contra el receptor de quimiocinas CCR7.
Cecilia Muñoz Calleja — Instituto de Investigación Sanitaria Hospital Universitario de La Princesa [Madrid, Spain]
![How can 3D structure knowledge help systems biology?](/media/1237/abdee57fbfad2649e0693f5362423b46.jpg?width=350&height=200&mode=crop)
How can 3D structure knowledge help systems biology?
Baldo Oliva Miguel — Universidad Pompeu Fabra (UPF) [Barcelona]
![The ins and outs of IL-7R-mediated signaling in leukemia](/media/1238/a6454d92d20908c31fd65a88e5d0bee8.jpg?width=350&height=200&mode=crop)
The ins and outs of IL-7R-mediated signaling in leukemia
João Barata — Instituto Medicina Molecular [Lisboa, Portugal]
![Defensa de tesis doctoral: Cáncer de ovario: cambios en el manejo y en el pronóstico debido a las nuevas clasificaciones FIGO y OMSy análisis de genes reparadores](/media/1239/f637eb922380bbd492c3a70aee8b7663.jpg?width=350&height=200&mode=crop)
Defensa de tesis doctoral: Cáncer de ovario: cambios en el manejo y en el pronóstico debido a las nuevas clasificaciones FIGO y OMSy análisis de genes reparadores
Mónica Morais Gomes-Ferreira —